Genomic Health to Present at the Canaccord Genuity 34th Annual Growth Conference

    Genomic Health to Present at the Canaccord Genuity 34th Annual Growth
                                  Conference

PR Newswire

REDWOOD CITY, Calif., Aug. 8, 2014

REDWOOD CITY, Calif., Aug. 8, 2014 /PRNewswire/ -- Genomic Health, Inc.
(Nasdaq: GHDX) today announced that Brad Cole, Chief Operating Officer and
Chief Financial Officer, will present at the 34^th Annual Canaccord Growth
Conference in Boston on Wednesday, August 13 at 10:30 a.m. Eastern Time (ET).

Genomic Health, Inc. logo

To access the live and subsequently archived webcast of the conference call,
go to theInvestor Relationssection of the company's website at
http://investor.genomichealth.com. Please connect to the website at least 15
minutes prior to the call to allow for any software download that may be
necessary.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of
genomic-based diagnostic tests that address both the overtreatment and optimal
treatment of early stage cancer, one of the greatest issues in healthcare
today. The company is applying its world-class scientific and commercial
expertise and infrastructure to lead the translation of massive amounts of
genomic datainto clinically-actionable results for treatment planning
throughout the cancer patient's journey, from screening and surveillance,
through diagnosis, treatment selection and monitoring. Genomic Health's lead
product, the Oncotype DX® breast cancer test, has been shown to predict the
likelihood of chemotherapy benefit as well as recurrence in invasive breast
cancer and has been shown to predict the likelihood of recurrence in ductal
carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic
Health provides the Oncotype DX colon cancer test, the first multi-gene
expression test developed for the assessment of risk of recurrence in patients
with stage II and stage III disease, and the Oncotype DX prostate cancer test,
which predicts disease aggressiveness in men with low risk disease. As of June
30, 2014, more than 19,000 physicians in over 70 countries had ordered more
than 465,000 Oncotype DX tests. The company is based in Redwood City,
California with European headquarters in Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com and follow the company on
Twitter: @GenomicHealth. To learn more about OncotypeDX tests, visit:
www.OncotypeDX.com, www.mybreastcancertreatment.org and
www.myprostatecancertreatment.org.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the attributes and focus of the company's product pipeline; the
applicability of clinical study results to actual outcomes; the ability of any
potential tests the company may develop to optimize cancer treatment; and the
ability of the company to develop and commercialize additional tests in the
future. Forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially, and reported results should
not be considered as an indication of future performance. These risks and
uncertainties include, but are not limited to: the risks and uncertainties
associated with the regulation of the company's tests; the results of clinical
studies; the applicability of clinical study results to actual outcomes; our
ability to develop and commercialize new tests and expand into new markets
domestically and internationally; the risk that the company may not obtain or
maintain sufficient levels of reimbursement, domestically or abroad, for its
existing tests and any future tests it may develop; the risks of competition;
unanticipated costs or delays in research and development efforts; the
company's ability to obtain capital when needed and the other risks set forth
in the company's filings with the Securities and Exchange Commission,
including the risks set forth in the company's quarterly report on Form 10-Q
for the quarter ended March 31, 2014. These forward-looking statements speak
only as of the date hereof. Genomic Health disclaims any obligation to update
these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and
DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their respective
owners.

Logo - http://photos.prnewswire.com/prnh/20130425/SF01493LOGO

SOURCE Genomic Health, Inc.

Contact: Investors: Emily Faucette, Genomic Health, 650-569-2824,
investors@genomichealth.com or Media: Victoria Steiner, Genomic Health,
650-569-2499, media@genomichealth.com
 
Press spacebar to pause and continue. Press esc to stop.